Selected Derivatives of Erythromycin B-In Silico and Anti-Malarial Studies

Erythromycin A is an established anti-bacterial agent against Gram-positive bacteria, but it is unstable to acid. This led to an evaluation of erythromycin B and its derivatives because these have improved acid stability. These compounds were investigated for their anti-malarial activities, by their in silico molecular docking into segments of the exit tunnel of the apicoplast ribosome from Plasmodium falciparum. This is believed to be the target of the erythromycin A derivative, azithromycin, which has mild anti-malarial activity. The erythromycin B derivatives were evaluated on the multi-drug (chloroquine, pyrimethamine, and sulfadoxine)-resistant strain K1 of P. falciparum for asexual growth inhibition on asynchronous culture. The erythromycin B derivatives were identified as active in vitro inhibitors of asexual growth of P. falciparum with low micro-molar IC50 values after a 72 h cycle. 5-Desosaminyl erythronolide B ethyl succinate showed low IC50 of 68.6 µM, d-erythromycin B 86.8 µM, and erythromycin B 9-oxime 146.0 µM on the multi-drug-resistant K1 of P. falciparum. Based on the molecular docking, it seems that a small number of favourable interactions or the presence of unfavourable interactions of investigated derivatives of erythromycin B with in silico constructed segment from the exit tunnel from the apicoplast of P. falciparum is the reason for their weak in vitro anti-malarial activities.


Introduction
Malaria remains a huge health problem worldwide with 229 million cases and 409,000 registered deaths reported in 2019 [1]. Due to the growing resistance from Southeast Asia to Africa to almost all anti-malarial drugs, it is clear that new therapeutic strategies are essential. Compounds like reversal agents (chemosentisizers, modulating agents) can restore the sensitivity in resistant cells [2,3]. Erythromycin A was first discovered as a reversal agent in multidrug-resistant cancer [4,5]. Antibiotics were found to possess antiplasmodial activity as early as 1940, but they were shown to be less effective and slow acting compared to chloroquine or quinine [3]. Erythromycin A possesses in vitro and in vivo anti-malarial activity [6]. Its anti-malarial action is improved in combination with chloroquine; therefore, its modulating effect is important in chloroquine resistance [3]. Anti-malarial activity has been described for other antibiotics such as co-trimoxazole, quinolones, tigecycline, mirincamycin, ketolides, fusidic acid, and thiopeptides [7]. Based on studies in Africa, co-trimoxazole can be used as an alternative in malaria prophylaxis, for children and adults, HIV (human immunodeficiency viruses) positive or negative patients on studies in Africa, co-trimoxazole can be used as an alternative in malaria prophylaxis, for children and adults, HIV (human immunodeficiency viruses) positive or negative patients and pregnant women [8][9][10][11]. Tigecycline must be administered intravenously; therefore, its use is reserved for patients with severe and complicated malaria, with delayed action similar to doxycycline [7].
The search for more active anti-malarial macrolides than the commercially available anti-malarial drugs has continued. A research group at GSK (GlaxoSmithKline) in Zagreb working on macrolides has published a series of ureas and thioureas of 15-membered azalides with the ureas containing a naphthyl moiety being the most active and 9a-N substituted 15-membered azalides with amide and amine functional groups with improved in vivo efficacy [12,13].
Azithromycin was shown to be a slow anti-malarial targeting parasite apicoplast (an organelle with four membranes containing 35 kb circular DNA (deoxyribonucleic acid) with replication, RNA (ribonucleic acid) transcription, and RNA-protein translation allowed [14]), giving IC50 in the nanomolar range [15], but better in combination with existing anti-malarial drugs [16].
Therefore, developing a more effective and safer anti-malarial from the class of macrolides is the aim of this research. Here, the in vitro anti-malarial activity of synthesised derivatives of erythromycin B (erythromycin B 9-oxime, 5-desosaminyl erythronolide B ethyl succinate, erythromycin B 2′- [3-(morpholinomethyl)benzoate], erythromycin B 2′- [3-(dimethylaminomethyl)benzoate], and 8-d-erythromycin B) (Figure 1), an acid-stable derivative of erythromycin A [17] have been investigated, including the use of molecular docking to give insight regarding the mechanism of action.

NMR (Nuclear Magnetic Resonance) Spectrometers Bruker Avance 300 Spectrometer
A Bruker Avance 300 spectrometer (Bruker, Billerica, MA, USA) was operated with an Oxford Instruments magnet (Billerica, MA, USA, magnetic field-7.04 Tesla). In this field, the 1 H resonated at 300 MHz and the 13 C at 75.47 MHz. A 5 mm QNP (Quattro Nucleus Probe-1 H, 13 C, 19 F, 31 P) probe with Z gradients was used.
Varian Unity 500 Spectrometer A Varian Unity 500 NMR spectrometer (Varian Medical Systems, Palo Alto, CA, USA) was operated with an Oxford Instruments magnet, magnetic field-11.74 Tesla. In this field, the 1 H resonated at 500 MHz. A 5 mm PFG (Pulse Field Gradient) probe was used. The temperature was controlled using the Varian VT unit with a precision of ±0.1 • C.
Bruker AMX 500 Spectrometer A Bruker AMX 500 (Bruker, Billerica, MA, USA) was operated with an Oxford Instruments magnet, magnetic field-11.74 Tesla. Either a TXI-Z (triple nucleus inverse probe with Z gradients) or a BBI (broad band inverse probe) was used.

Mass Spectrometer
Electrospray ionisation-mass spectra (ESI-MS) were acquired on a Micromass Platform mass spectrometer (Waters Corporation, Milford, MA, USA), and the data were analysed using the program PLATFORM with a Masslynx data system. The sample (10 µL) was injected using a Hewlett Packard auto-sampler, and the machine was operated at a cone value of 30 eV, at 80 • C. For identification purposes, all samples (0.2 mg) were prepared in acetonitrile (1 mL). For degradation studies, a deuterated Britton-Robinson buffer was used unless otherwise stated. Water was used as the solvent for running the samples unless otherwise stated.

pH Meter
All pH measurements were carried out using a Mettler Delta 320 (Mettler Toledo, Greifensee, Switzerland), equipped with a combination electrode (Gelpas, BDH, Poole, UK). The pH of the deuterated buffers was measured on the Hanna pH 213 (Hanna Instruments Inc., Woonsocket, RI, USA), equipped with a combination electrode (Gelpas, BDH, Poole, UK) and a temperature probe. Buffer reference standards (4.00 ± 0.01, 7.00 ± 0.01, and 10.00 ± 0.01 at 25 • C) (Sigma-Aldrich, Saint Louis, MO, USA) were used to calibrate the pH meters by a two-point calibration method. All pH measurements were at room temperature and are reported uncorrected.

Melting Point Apparatus
All melting points were determined using a Bibby SMP-10 (Stuart Scientific, Staffordshire, UK) melting point apparatus and are reported uncorrected. The samples were placed in a capillary tube and inserted in the melting point apparatus and were heated at a rate of 1 • C/min until the compound melted. All the TLC experiments were carried on already-prepared aluminium-backed silica gel 60 F 254 (Merck, Darmstadt, Germany) plates without any prior activation. Spots were applied using a 5 µL capillary, and EtOAc-CH 3 OH-25% NH 3 (85:10:5) was used as the mobile phase [18]. The plates were dried in the oven for 1 min and then were sprayed with p-anisaldehyde: sulphuric acid: ethanol mixture (1:1:9). The plates were dried in the oven set at 110 • C for 5 min, and the R f value for each of the compounds was determined.
2.2. Two-Dimensional NMR Spectroscopy 2.2.1. TOCSY and DQF-COSY For structural determination, both the TOCSY (Total Correlated Spectroscopy) and the DQF-COSY (Double Quantum Filtered Correlated Spectroscopy) spectra were obtained at ambient temperature on the Varian Unity 500 spectrometer. In the TOCSY experiment, cross-peaks were found for all the protons in the same spin system. The COSY spectrum indicated all the spin-spin coupled protons. For both the experiments, 2048 × 2048 complex points were acquired. The spectra were processed using negative line broadening and Gaussian multiplication for resolution enhancement.

HMQC and HMBC
HMBC (Heteronuclear Multiple Bond Connectivity) and HMQC (Heteronuclear Multiple Quantum Coherence) spectra were acquired on the Varian Unity 500 spectrometer. An HMBC spectrum was acquired by using a long-range 1 H-13 C COSY pulse sequence to give a two-dimensional spectrum with 13 C chemical shifts on one axis and 1 H chemical shifts on the other. An HMQC indicated single-bond correlation between 13 C and the proton to which, it was directly attached.

DOSY
Erythromycin B 2 -ethyl succinate was dissolved in deuterated Britton-Robinson buffer at an apparent pH 2.0 to give concentration of 4 mM and was degraded over two hours. The degraded samples were cooled to ambient temperature and a high resolution DOSY (Diffusion-Ordered Spectroscopy) spectrum was acquired using a ONESHOT DOSY pulse sequence. Twelve spectra were acquired, with gradient pulses of 2.9 ms. The FIDDLE (free induction decay deconvolution for line shape enhancement) algorithm [19] was used to correct line shapes using TSP as a reference standard. DOSY spectra were constructed after baseline correction by taking the first echo spectrum and distributing the intensities of the individual signals in the second dimension according to their respective diffusion coefficient [20,21].

Synthesis of Erythromycin B Derivatives
Erythromycin B was a gift from Dr. Warren Mann, Abbott International Division, which was used without further purification. Acetone (GPR grade, BDH, Poole, UK) dried over anhydrous sodium sulphate (Na 2 SO 4 ) was used as a solvent in most syntheses, unless stated otherwise. The water work-up refers to washing the organic layer with water (2 × 50 mL) and 50 mL brine (saturated sodium chloride solution).

Synthesis of Erythromycin B Oxime The First Method
This method was adapted from Gasc et al. (1991) [22]. Erythromycin B (5.0 g) was dissolved in 50 mL methanol (GPR grade, BDH, UK, previously dried over sodium sulphate) followed by addition of 2.46 mL triethylamine and 2.46 g hydroxylamine hydrochloride (Sigma-Aldrich, Burlington, MA, USA). The mixture was refluxed for 24 h. After complete dissolution, the progressive crystallisation of erythromycin B oxime hydrochloride was observed. The reaction mixture was cooled to 2 • C for 1 h. The crystals were separated and washed three times with 2.5 mL cooled methanol. To the suspension of erythromycin oxime hydrochloride in 15 mL methanol (20 • C), 3.26 mL of ammonium hydroxide solution (20%) was added. After stirring for 30 min, 3.26 mL of water was added to the solution to give 1. 8 [23]. Erythromycin B (5.0 g), 2.49 g anhydrous sodium acetate (Fisher Scientific, Loughborough, UK) and 1.75 g hydroxylamine hydrochloride (Sigma-Aldrich, Burlington, MA, USA) were added to 20 mL methanol, and the suspension was stirred at room temperature for 6 days and then refluxed for 30 min. The reaction mixture was concentrated in vacuo to about half the original volume and poured into 10 mL water. The resulting crystals were filtered, triturated successively with water, saturated NaHCO 3 solution and water, and then filtered.

Synthesis of Erythromycin B 2 -(3-chloromethylbenzoate) (EBCMB)
EBCMB acts as a starting material for all the erythromycin 2 -(N-substituted 3-or 4aminomethylbenzoate) esters. It was prepared by adapting the procedure used by Jensen et al. (1990) [24]. 3-Chloromethylbenzoyl chloride (1.25 mL, Sigma-Aldrich, Burlington, MA, USA) in 5 mL acetone was added dropwise to a mixture of erythromycin B (5 g) and 1 g NaHCO 3 in 200 mL acetone. The resulting solution was stirred at room temperature overnight. The residue was stirred with 100 mL phosphate buffer (pH 6.5) for 15 min followed by a water work-up. The organic layer was dried in vacuo, and the crystalline product was recrystallised from ethyl acetate.

Synchronisation of K1 P. falciparum
The K1 strain of P. falciparum was cultivated until ≥8% parasitaemia was obtained, with neat prevalence of ring stages. The culture was then transferred to a falcon tube and centrifuged at 3500 rpm for 5 min at 20 • C. Supernatant was removed, and the pellet was re-suspended in 5 mL of aqueous 5% sorbitol at room temperature for 5 min and further centrifuged as before. The supernatant was removed, and the pellet was washed 3 times with complete media before setting up a new culture. The pellet was re-suspended in complete media with enough purified 50% RBCs (red blood cells) to obtain 5% final haematocrit.

Determination of IC 50 in K1 P. falciparum
Here, 1% infected RBCs with P. falciparum K1 strain at ring stage were exposed to 9 dilutions at concentrations of 3.05 nM-200 µM (4-fold serial dilution) of compounds from 50 mM stock solutions. 100 µL of culture volume was added in 96-well plates with 100 µL drug dilutions. Untreated infected RBCs served as positive control while the uninfected RBCs was a negative control. The plates were incubated for 72 h at 37 • C, 5% CO 2 , and 5% O 2 in N 2 . Following the incubation, 150 µL of media was carefully removed, and 150 µL of SYBR (Synergy Brands) Green solution (prepared by adding 2 µL of 10,000 X SYBR Green in 4 mL of phosphate buffer saline (PBS)) was added to each well. The plates were kept in the dark for 45 min at room temperature. The fluorescence intensity was measured using a microplate reader (Genius Tecan) set at 485 nm excitation and 535 nm emission wavelengths. Chloroquine was included as a control drug.
The IC 50 values were determined using Graph Pad Prism 5.0. Values were calculated using non-linear regression by using log-transformed drug concentration plotted against dose-response. Parasitaemia was calculated and normalised relative to response on the controls (cultures without drug).

Molecular Docking Studies
Molecular docking studies were performed using the Patchdock web server with the Patchdock molecular docking algorithm based on shape complementarity principles [28][29][30]. The input is set consisting of the pdb files of the receptor molecule and the ligand molecule. The pdb files of the ligand molecules consisted of folded-out structures obtained in the unconstrained conformational search for all investigated erythromycin B derivatives, except erythromycin B 2 -[3-(dimethylaminomethyl)benzoate], where we used the global minimum of the constrained conformational search. The output is a list of the potential complexes sorted by the shape complementarity principles.
Ten best results from docking analysis using Patchdock algorithm were submitted to FireDock for refinement [31,32].
Visualisation of the results and the formation of 2D diagrams were performed using Discovery Studio 2021 Client (Dessault Systems Biovia Corp., San Diego, CA, USA).

Synthesis of N-Substituted 2 -(3-aminomethylbenzoate) Esters of Erythromycin B
N-substituted 2 -(3-aminomethylbenzoate) esters of erythromycin B were synthesised in two steps. In the first step, erythromycin B was esterified at C-2 with 3-chloromethylbenzoyl chloride. In the second step, the product erythromycin B 2 -[3-chloromethylbenzoate] was heated at reflux with the appropriate amine (R) in the presence of sodium iodide as a catalyst (Scheme 1) [33].

In Vitro Investigation of Synthesised Erythromycin B Derivatives against P. falciparum K1 Strain
Erythromycin B and its derivatives were shown to possess anti-bacterial activity [17], but they have never been investigated as anti-malarials. Due to the fact that erythromycin B possesses acid stability [17], we hypothesised that they would show better anti-malarial Scheme 1. Synthesis of N-substituted 2 -(3-aminomethylbenzoate) esters from erythromycin B as a starting macrolide.

In Vitro Investigation of Synthesised Erythromycin B Derivatives against P. falciparum K1 Strain
Erythromycin B and its derivatives were shown to possess anti-bacterial activity [17], but they have never been investigated as anti-malarials. Due to the fact that erythromycin B possesses acid stability [17], we hypothesised that they would show better anti-malarial activity when compared with erythromycin A. Therefore, we selected several derivatives of erythromycin B for evaluation: erythromycin B 9-oxime, 5-desosaminyl erythronolide B ethyl succinate, erythromycin B 2 -[3-(morpholinomethyl)benzoate], erythromycin B 2 -[3-(dimethylaminomethyl)benzoate], and 8-d-erythromycin B.
A 1% parasitised culture at ring stage was treated with the compounds for 72 h at concentrations of 3.05 nM-200 µM (four-fold serial dilution) against the P. falciparum K1 strain, and the growth was measured using the SYBR Green-based plate reader assay.
SYBR Green is a sensitive DNA stain that can bind to the double-stranded parasite DNA, and once intercalated, it becomes fluorescent [34]. SYBR Green assay offers a quick, inexpensive, and straightforward method to test parasites' susceptibility of anti-malarial drugs [35]. The assay takes the advantage of the fact that the parasite-host cells (healthy human mature erythrocytes) lack DNA; therefore, the fluorescence intensity reflects parasite growth.
The investigated compounds exhibited anti-malarial activities with micromolar IC 50 values against the multi-drug-resistant P. falciparum strain K1 (Figure 2). Erythromycin

Unconstrained Conformational Search of the Investigated Derivatives of Erythromycin B in Chloroform
We chose chloroform as a solvent because it was previously found that the most commonly used dielectric constant for proteins is 4; inside the protein according to the recent investigation, it is 6-7 [36]; and inside nucleic acids, it is 2 [37].
Folded-out and folded-in terms were defined by Everett et al. (1990) [38], and it was shown that erythromycin A mainly possesses characteristics of the folded-out conformational type [39]. The distances (Å) among the characteristic hydrogens for folded-out and folded-in conformations were measured for selected derivatives of erythromycin B in chloroform as a solvent, which are given in Table 1, together with the energies of global minima and the number of times they repeat.
The global minimum of erythromycin 9-oxime in chloroform is neither folded out nor folded in, although the H4-H18 and H3-H8 distances correspond to a typical folded-in conformation. Erythromycin B 2 -[3-(morpholinomethyl) benzoate] in chloroform has a global minimum, which is a variation of a folded-out conformation. The global minimum of erythromycin B 2 -[3-(dimethylaminomethyl)benzoate] in chloroform is a typical foldedin conformation. 5-Desosaminyl erythronolide B ethyl succinate in chloroform shows a global minimum that is neither folded-out nor folded-in, but is different from the global minimum of erythromycin B 2 -[3-(morpholinomethyl) benzoate]. The global minimum of 8-d-erythromycin B is a folded-in conformation.
Previously, it was shown that the active conformation of the macrolide antibiotics bound weakly to bacterial ribosomes, such as clarithromycin, erythromycin A, and azithromycin [39], is mainly the folded-out conformation. None of the global minima for the investigated derivatives of erythromycin B is a typical folded-out conformation. Typical folded-out conformations for erythromycin B and 8-d-erythromycin B were found bound weakly to the bacterial ribosomes [27]; therefore, folded-out conformations were used for the docking analysis as the active conformations of the ligands-investigated derivatives of erythromycin B (erythromycin B 9-oxime, erythromycin B 2 -[3-(morpholinomethyl) benzoate], erythromycin

Docking Analysis of the Investigated Derivatives of Erythromycin B into In Silico Constructed Segment of the Exit Tunnel from the Apicoplast Ribosome of P. falciparum
The docking analysis of erythromycin B derivatives into in silico constructed exit tunnel from apicoplast ribosome from P. falciparum was complex. The majority of free or commercially available software for molecular docking are either suitable for proteins or RNAs as receptors, but not for complexes which contain both protein and RNA residues. We chose PatchDock for our docking analysis because it relies on different principles-on shape complementarity [26][27][28]-compared to other software.
For all docking analyses with derivatives of erythromycin B as ligands and complexes containing protein and three domains of 23S rRNAs as receptors, results were characterised with the parameters presented in Table 2, such as score, area, and ACE.
Ten best results of performed molecular docking for each investigated erythromycin B derivatives were subjected to FireDock refinement. Solution number, global energy, attractive van der Waals, repulsive van der Waals, and ACE for investigated erythromycin B derivatives are given in Table 3.
Erythromycin B 2 -[3-(dimethylaminomethyl)benzoate] shows very similar behaviour regarding present interactions in the best-ranked solution structure after refinement using Firedock algorithm with the receptor: π-alkyl (pink circles), carbon hydrogen bond (light-blue circles), and an unfavourable bump (red circle) ( Figure 5). 5-Desosaminyl erythronolide B ethyl succinate shows the following interactions with the nucleotides in the best-ranked solution: π-σ (violet circles), π-alkyl (pink circles), and carbon hydrogen bond (light-blue circles), as well as an unfavourable bump (red circle) ( Figure 6). Table 2. Score, area, and ACE (atomic contact energy) of top ten results based on shape complementarity principles for docking analysis of investigated derivatives of erythromycin B with complex of protein and three domains of 23S rRNA. The docking results, followed by the refinement, provide a good explanation for the results of the anti-malarial tests. The highest number of unfavourable interactions is shown by erythromycin B 2 -[3-(morpholinomethyl)benzoate]; therefore, it is not surprising that this compound does not show any anti-malarial activity (IC 50 > 200 µM). Erythromycin B 9-oxime does not show any unfavourable interactions, different from others, but it shows only five favourable interactions, the lowest number among the investigated erythromycin B derivatives. The highest number of favourable interactions was shown in case of 5-desosaminyl erythronolide B ethyl succinate; therefore, it is in good correlation with found IC 50 value, which is the lowest among the investigated derivatives, i.e., the highest anti-malarial activity among the tested compounds. Erythromycin B 2 -[3-(dimethylaminomethyl)benzoate] shows a higher number of favourable interactions (8) compared to 8-d-erythromycin B (7), but the last derivative shows interaction with more contribution (π-Lone pair); therefore, this is the reason why 8-d-erythromycin B shows better anti-malarial activity compared to erythromycin B 2 -[3-(dimethylaminomethyl)benzoate]. π-Lone pair is the interaction shared both between 8-d-erythromycin B and erythromycin B 9-oxime, but because of the higher number of favourable interactions shown by 8-derythromycin B, it shows better anti-malarial activity. without predetermined binding sites only interactions with nucleotides: π-σ (violet circles), and π-Lone pair (light green circles) and π-alkyl (pink circles) (Figure 3). Erythromycin B 2′- [3-(morpholinomethyl)benzoate] under the same circumstances shows the solution with the following interactions with nucleotides: π-σ (violet circles), π-alkyl (pink circles), and carbon-hydrogen bond (light blue circles), as well as unfavourable bumps (red circles) (Figure 4).  Erythromycin B 2′- [3-(dimethylaminomethyl)benzoate] shows very similar behaviour regarding present interactions in the best-ranked solution structure after refinement using Firedock algorithm with the receptor: π-alkyl (pink circles), carbon hydrogen bond (light-blue circles), and an unfavourable bump (red circle) ( Figure 5). 5-Desosaminyl erythronolide B ethyl succinate shows the following interactions with the nucleotides in the best-ranked solution: π-σ (violet circles), π-alkyl (pink circles), and carbon hydrogen bond (light-blue circles), as well as an unfavourable bump (red circle) ( Figure 6). without predetermined binding sites only interactions with nucleotides: π-σ (violet circles), and π-Lone pair (light green circles) and π-alkyl (pink circles) (Figure 3). Erythromycin B 2′- [3-(morpholinomethyl)benzoate] under the same circumstances shows the solution with the following interactions with nucleotides: π-σ (violet circles), π-alkyl (pink circles), and carbon-hydrogen bond (light blue circles), as well as unfavourable bumps (red circles) (Figure 4).  Erythromycin B 2′-[3-(dimethylaminomethyl)benzoate] shows very similar behaviour regarding present interactions in the best-ranked solution structure after refinement using Firedock algorithm with the receptor: π-alkyl (pink circles), carbon hydrogen bond (light-blue circles), and an unfavourable bump (red circle) ( Figure 5). 5-Desosaminyl erythronolide B ethyl succinate shows the following interactions with the nucleotides in the best-ranked solution: π-σ (violet circles), π-alkyl (pink circles), and carbon hydrogen bond (light-blue circles), as well as an unfavourable bump (red circle) ( Figure 6).  The docking results, followed by the refinement, provide a good explanation for the results of the anti-malarial tests. The highest number of unfavourable interactions is shown by erythromycin B 2′-[3-(morpholinomethyl)benzoate]; therefore, it is not surprising that this compound does not show any anti-malarial activity (IC50 > 200 µM). Erythromycin B 9-oxime does not show any unfavourable interactions, different from others, but  8-d-Erythromycin B shows some general patterns regarding the interactions with the nucleotides from the receptor-in silico made segment of the exit tunnel from apicoplast ribosome of P. falciparum: unfavourable bump (red circle), carbon hydrogen bond (light blue circle), π-Lone pair (light green circle), and π-alkyl (pink circle) (Figure 7). The docking results, followed by the refinement, provide a good explanation for the results of the anti-malarial tests. The highest number of unfavourable interactions is shown by erythromycin B 2′-[3-(morpholinomethyl)benzoate]; therefore, it is not surprising that this compound does not show any anti-malarial activity (IC50 > 200 µM). Erythromycin B 9-oxime does not show any unfavourable interactions, different from others, but It can be speculated that the small number of favourable interactions or the presence of unfavourable interactions is the reason for weak anti-malarial activity of investigated derivatives of erythromycin B. Molecular docking can also be a good tool for the prediction of anti-malarial activity of derivatives with previously undetermined anti-malarial activity. In the future, we will broaden our investigation using both in silico tools and experimental results.

Conclusions
Five derivatives of erythromycin B were synthesised and evaluated for their antimalarial activity against multi-drug-resistant K1 strain of P. falciparum. They do not show significant anti-malarial activity, ranging from 68.